Affiliation:
1. Department of Epidemiology Gillings School of Global Public Health, University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
2. Department of Population Health Sciences Weill Cornell Medical College New York New York USA
3. Endocrinology Service, Department of Subspecialty Medicine Memorial Sloan Kettering Cancer Center New York New York USA
Abstract
AbstractAimThe transition to the ICD‐10‐CM coding system has reduced the utility of hypoglycaemia algorithms based on ICD‐9‐CM diagnosis codes in real‐world studies of antidiabetic drugs. We mapped a validated ICD‐9‐CM hypoglycaemia algorithm to ICD‐10‐CM codes to create an ICD‐10‐CM hypoglycaemia algorithm and assessed its performance in identifying severe hypoglycaemia.Materials and MethodsWe assembled a cohort of Medicare patients with DM and linked electronic health record (EHR) data to the University of North Carolina Health System and identified candidate severe hypoglycaemia events from their Medicare claims using the ICD‐10‐CM hypoglycaemia algorithm. We confirmed severe hypoglycaemia by EHR review and computed a positive predictive value (PPV) of the algorithm to assess its performance. We refined the algorithm by removing poor performing codes (PPV ≤0.5) and computed a Cohen's statistic to evaluate the agreement of the EHR reviews.ResultsThe algorithm identified 642 candidate severe hypoglycaemia events, and we confirmed 455 as true severe hypoglycaemia events, PPV of 0.709 (95% confidence interval: 0.672, 0.744). When we refined the algorithm, the PPV increased to 0.893 (0.862, 0.918) and missed <2.42% (<11) true severe hypoglycaemia events. Agreement between reviewers was high, = 0.93 (0.89, 0.97).ConclusionsWe translated an ICD‐9‐CM hypoglycaemia algorithm to an ICD‐10‐CM version and found its performance was modest. The performance of the algorithm improved by removing poor performing codes at the trade‐off of missing very few severe hypoglycaemia events. The algorithm has the potential to be used to identify severe hypoglycaemia in real‐world studies of antidiabetic drugs.
Funder
National Cancer Institute
Patient-Centered Outcomes Research Institute
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献